These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 23909024

  • 1. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
    Aschermann Z, Kovács N, Komoly S.
    Ideggyogy Sz; 2013 May 30; 66(5-6):209-10. PubMed ID: 23909024
    [No Abstract] [Full Text] [Related]

  • 2. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A, Nagy H, Radics P, Tóth A, Tamás G.
    Ideggyogy Sz; 2013 Nov 30; 66(11-12):365-71. PubMed ID: 24555235
    [Abstract] [Full Text] [Related]

  • 3. Continuous levodopa infusion is better—for now.
    Nutt JG.
    Mov Disord; 2015 Apr 30; 30(4):443-5. PubMed ID: 25757898
    [No Abstract] [Full Text] [Related]

  • 4. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov 30; 11(135):101-6. PubMed ID: 24165688
    [Abstract] [Full Text] [Related]

  • 5. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ, Sesar-Ignacio Á.
    Rev Neurol; 2012 Nov 30; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [Abstract] [Full Text] [Related]

  • 6. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Nov 30; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 7. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
    Ludin HP, Surber Ch.
    Praxis (Bern 1994); 2006 Dec 20; 95(51-52):2013-8. PubMed ID: 17294589
    [Abstract] [Full Text] [Related]

  • 8. Myths and realities of continuous dopaminergic stimulation.
    Pirtošek Z.
    Psychiatr Danub; 2011 Mar 20; 23(1):80-3. PubMed ID: 21448103
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P, Kubová D, Bareš M, Hortová H, Streitová H, Rektor I, Znojil V.
    Mov Disord; 2002 Jan 20; 17(1):188-91. PubMed ID: 11835461
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan 31; 47(1201):12. PubMed ID: 15706700
    [Abstract] [Full Text] [Related]

  • 20. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr 31; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.